Pfizer nabs RSV therapeutic biotech ReViral in quick $525M bolt-on

Pfizer has had plenty of success in respiratory syncytial virus (RSV) lately, with multiple FDA designations and clinical advancements for its vaccine candidate. But that’s not enough for the pharma giant. Today, the New York-based behemoth is acquiring ReViral and its collection of therapeutics for the pesky respiratory virus for $525 million.